Efficacy and safety of docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen for Chinese triple-negative local advanced breast cancer patients : A prospective, open, and unicentric phase II clinical trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 6, 2013, Pages 545-551

  Fei, Fei ^a,b   Chen, Canming ^a,b   Xue, Jingyan ^a,b   Di, Gen Hong ^a,b   Lu, Jin Song ^a,b   Liu, Guang Yu ^a,b   Shao, Zhi Ming ^a,b   Wu, Jiong ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Axillary lymph node (AXLN); Local advanced breast cancer (LABC); Sentinel lymph node (SLN); Sentinel lymph node biopsy (SLNB); Supraclavicular lymph node (SCL); Triple negative local advanced breast cancer (TNLABC)

Indexed keywords

DOCETAXEL; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; ADULT; ALOPECIA; ANEMIA; ARTICLE; CANCER STAGING; CHINESE; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VOMITING; YOUNG ADULT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; TAXOIDS; TRANSAMINASES; TREATMENT OUTCOME; VOMITING;

EID: 84892572211     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31825d5317     Document Type: Article

References (30)

1. Dent R, Trudeau M, Pritchard KI, et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-4434.
2. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and Her2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109:1721-1728.
3. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor hemo sensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329-2334.
4. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative earlystage breast cancer. J Clin Oncol. 2006;24:5652-5657.
5. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235-244, doi: 10.1016/S1470-2045(07) 70074-8.
6. Kouroussis C, Agelaki S, Mavroudis D, et al. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Anticancer Res. 2003;23:785-791.
7. Lee J, Kang WK, Kwon JM, et al. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Ann Oncol. 2007;18:88-92.
8. Louvet C, Andre T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002;20:4543-4548.
9. Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 2008;19: 1847-1852.
10. Bhattacharyya A, Ear US, Koller BH, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA crosslinking agent cisplatin. J Biol Chem. 2000;275:23899-23903.
11. Moynahan ME, Cui TY, Jasin M, et al. repair, mitomycin-C resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 2001;61:4842-4850.
12. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145-1153.
13. Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25:2650-2655.
14. Garufi C, Nistico C, Brienza S, et al. Single-Agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol. 2001;12:179-182.
15. Zelek L, Cottu P, Tubiana-Hulin M, et al. Phase II study of oxaliplatin and fluorouracil in taxane-And anthracycline-pretreated breast cancer patients. J Clin Oncol. 2002;20:2551-2558.
16. Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. Ann Oncol. 2003;14:537-542.
17. Thuss-Patience PC, von Minckwitz G, Kretzschmar A, et al. Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: a preliminary phase II study. Anticancer Drugs. 2003;14:549-553.
18. Airoldi M, Cattel L, Passera R, et al. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. Am J Clin Oncol. 2006;29:490-494.
19. Caruba T, Cottu PH, Madelaine-Chambrin I, et al. Gemcitabineoxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients. Breast J. 2007;13:165-171.
20. Petit T, Benider A, Yovine A, et al. Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracyclineand taxane-pre-Treated metastatic breast cancer. Anticancer Drugs. 2006;17:337-343.
21. Smith IE, A'Hern RP, Coombes GA, et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-Adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol. 2004;15:751-758.
22. Amat S, Bougnoux P, Penault-Llorca F, et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer. 2003;88: 1339-1345.
23. Buosi R, Saggia C, Zanoli V, et al. Docetaxel and Oxaliplatin in weekly administration in solid tumors: dose-finding study. Ann Oncol. 2002;13(suppl 3):82. Abstract F13.
24. Ferrandin a G, Ludovisi M, Deincenzo R, et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol. 2007;18:1348-1353.
25. Al-Batran S-E, Homann N, Hartmann JT, et al. 5-fluorourail, leucovorin and oxaliplatin with or without docetaxel in older adult patients with esophagogastric cancer: preliminary results from the FLOT65 + trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). 2009 Joint Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Oncology: MIS04525773.
26. Xu H, Grossman E, Namgoong SY, et al. Enhanced antitumor activity of TLK286 in combination with oxaliplatin, carboplatin, doxorubicin, paclitaxel and docetaxel in human colorectal, ovarian and breast cancer cell lines. Proc Am Assoc Cancer Res. 2003;44:390-391. Abstract 1722.
27. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678-5685.
28. Liedtke A., Mazouni C., Hess KR, et al. Response to neoadjuvant therapy and long-Term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-1281.
29. Le Tourneau C, Dettwiler S, Laurence V, et al. 47% pathologic complete response rate to anthracyclines-based associated with high cyclophosphamide doses neoadjuvant chemotherapy in basallike and triple negative breast cancer patients. Breast Cancer Res Treat. 2007;106(suppl 1):S169. Abstract 4010.
30. Allada N, Osborne CR, Xie X-J, et al. Pathological and clinical outcomes in response to neoadjuvant chemotherapy: a comparison of basal-like, hormone receptor-positive and HER2-positive breast cancers. Breast Cancer Res Treat. 2007;106(suppl 1):S232. Abstract 5076.